Nivolumab
Collecting Duct Renal Cell Carcinoma
Bradley A. McGregor, MDmonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Collecting Duct Renal Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bms-907351 Bradley A. McGregor, MD | Phase 2 | B |
Bms-907351 Bradley A. McGregor, MD | Phase 2 | B |
Ipilimumab Bradley A. McGregor, MD | Phase 2 | CCC |
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4) Giuseppe Procopio | Phase 2 | CCC |
Axitinib Peking University Cancer Hospital & Institute | Phase 2 | CCC |
Pamiparib Jonsson Comprehensive Cancer Center | Phase 2 | CCC |
Pembrolizumab Giuseppe Procopio | Phase 2 | CCC |
gw786034 Mayo Clinic | Phase 2 | NR |
Same molecule, other indications
Nivolumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →